David Smith1, Thomas R J Heathman2, Alex Klarer2, Courtney LeBlon2, Yasuhiko Tada3, Brian Hampson2. 1. Hitachi Chemical Advanced Therapeutics Solutions LLC, Allendale, NJ, USA. David.smith.ys@hitachi-chem.com. 2. Hitachi Chemical Advanced Therapeutics Solutions LLC, Allendale, NJ, USA. 3. Hitachi Chemical Company, Yokohama, Japan.
Abstract
PURPOSE OF REVIEW: Many cell therapy products are beginning to reach the commercial finish line and a rapidly escalating pipeline of products are in clinical development. The need to develop manufacturing capability that will support a successful commercial business model has become a top priority as many cell therapy developers look to secure long-term visions to enable both funding and treatment success. RECENT FINDINGS: Manufacturing automation is both highly compelling and very challenging at the same time as a key tactic to address quality, cost of goods, scale, and sustainability that are fundamental drivers for commercially viable manufacturing. This paper presents an overview and strategic drivers for application of automation to cell therapy manufacturing. It also explores unique automation considerations for patient-specific cell therapy (PSCT) where each full-scale lot is for one patient vs off-the-shelf cell therapy (OTSCT) where a full-scale lot will treat many patients, and finally some practical considerations for implementing automation.
PURPOSE OF REVIEW: Many cell therapy products are beginning to reach the commercial finish line and a rapidly escalating pipeline of products are in clinical development. The need to develop manufacturing capability that will support a successful commercial business model has become a top priority as many cell therapy developers look to secure long-term visions to enable both funding and treatment success. RECENT FINDINGS: Manufacturing automation is both highly compelling and very challenging at the same time as a key tactic to address quality, cost of goods, scale, and sustainability that are fundamental drivers for commercially viable manufacturing. This paper presents an overview and strategic drivers for application of automation to cell therapy manufacturing. It also explores unique automation considerations for patient-specific cell therapy (PSCT) where each full-scale lot is for one patient vs off-the-shelf cell therapy (OTSCT) where a full-scale lot will treat many patients, and finally some practical considerations for implementing automation.
Authors: Elizabeth Csaszar; Daniel C Kirouac; Mei Yu; WeiJia Wang; Wenlian Qiao; Michael P Cooke; Anthony E Boitano; Caryn Ito; Peter W Zandstra Journal: Cell Stem Cell Date: 2012-02-03 Impact factor: 24.633
Authors: Qasim A Rafiq; Karen Twomey; Michael Kulik; Christian Leschke; John O'Dea; Sarah Callens; Chiara Gentili; Frank P Barry; Mary Murphy Journal: Regen Med Date: 2016-05-11 Impact factor: 3.806
Authors: Yonatan Y Lipsitz; William D Milligan; Ian Fitzpatrick; Evelien Stalmeijer; Suzanne S Farid; Kah Yong Tan; David Smith; Robert Perry; Jessica Carmen; Allen Chen; Charles Mooney; John Fink Journal: Cytotherapy Date: 2017-09-19 Impact factor: 5.414
Authors: Monica Gunetti; Sara Castiglia; Deborah Rustichelli; Katia Mareschi; Fiorella Sanavio; Michela Muraro; Elena Signorino; Laura Castello; Ivana Ferrero; Franca Fagioli Journal: J Transl Med Date: 2012-05-31 Impact factor: 5.531